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Living far away from specialized care centers is a potential
barrier to the delivery of quality health care and has been
associated with adverse outcomes. To assess mortality as
a function of distance from the closest hemodialysis unit,
and as a function of rural rather than urban residence, we
analyzed prospectively collected data on 726,347 adults
initiating chronic hemodialysis in the United States over a
13-year period. Participants were classified into categories of
0–10 (referent), 11–25, 26–45, 46–100, and remote living over
100 miles from the closest hemodialysis unit. After a median
follow-up of 2.7 years (range 0 to 12.7 years), 368,569
patients died. Compared to the referent group, the adjusted
hazard ratio of death was 1.01, 0.99, 0.96, and 1.21,
respectively. When residence location was classified using
rural–urban commuter areas, 16.5, 66.8, and 16.7% of
patients lived in urban, micropolitan, and metropolitan areas,
respectively. Compared with those living in metropolitan
areas, the adjusted hazard ratio of mortality among patients
residing in micropolitan and rural communities was 1.02 and
1.01, respectively. Thus, remote but not rural residence was
associated with increased mortality among patients initiating
chronic hemodialysis treatment in the United States.
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Several recent studies suggest that health outcomes are worse
for remote-dwelling patients with chronic kidney disease and
kidney failure, compared with otherwise similar patients living
closer to specialist care.1–3 Potential inequities in access to
health care as a result of remote residence location are
particularly relevant for patients treated with hemodialysis—
which for most patients requires travel to a treatment facility
three times per week. The burden of travel to dialysis has been
associated with a lower health-related quality of life and an
increased risk of mortality for patients with longer travel times
to hemodialysis compared with those with shorter travel times.4
Rural vs. urban place of dwelling is an alternative measure
of geographical access and is often used to evaluate acces-
sibility to health care. Reported outcomes for urban- vs.
rural-dwelling patients with chronic kidney disease have
varied.5,6 In one large study from the United States, survival
was comparable for rural- and urban-dwelling hemodialysis
patients, although the distance or travel time to the nearest
hemodialysis center was not evaluated.7 A large US popula-
tion-based study reported that the likelihood of receiving a
kidney transplant (when adjusted for factors including
distance from care) was slightly higher for rural compared
urban dwellers.8 An estimated one-third of dialysis units in
the United States are located in rural areas.7 As distance to
specialist care may differ substantially between rural dialysis
units, classifying location as rural vs. urban may not
adequately capture access to care. How travel distance to
the nearest hemodialysis center and urban vs. rural dwelling
is related to the risk of mortality in hemodialysis patients in
the United States is unknown.
Ensuring equitable access to high-quality health care for
patients with kidney failure is an important objective. To
achieve this objective, further examination of the association
between residence location and outcomes is required. We
evaluated the association between place of residence and
mortality among incident hemodialysis patients in the
United States using (1) the shortest driving distance to the
closest hemodialysis center as determined by patient zip code
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and geographic information systems software and (2) the
rural–urban commuting area (RUCA) code to classify the
degree to which the residence location of each patient was
rural or urban. We hypothesized that the risk of mortality
would be higher for patients living further away from their
dialysis center and for rural vs. urban dwellers.
RESULTS
Patient characteristics
Among the 747,150 patients who initiated chronic hemodial-
ysis during the study period, information on the distance
between residence location and the closest hemodialysis
center could be determined for 726,347 (97.2%). The 20,803
(2.8%) patients with missing or invalid zip codes were
excluded. Patients who lived further away from the closest
dialysis center were less likely to be black or have
hypertension as a cause of end-stage renal disease (ESRD)
than patients living closer (Po0.0001; Table 1). When
compared with patients living closest to their dialysis unit,
patients living 4100 miles away had lower rates of coronary
disease, peripheral vascular disease, congestive heart failure,
and chronic obstructive pulmonary disease. Patients residing
further from the hemodialysis center were more likely to live
in a rural area. However, among patients residing in a rural
area, a substantial proportion, 80.2%, lived within 25 miles of
the closest hemodialysis center.
Overall, 127,605 (17.6%) of patients received a kidney
transplant during follow-up. Although 26.7% of the study
population changed residence location during follow-up,
most patients (90.8%) remained in the same distance category
throughout the study. Of the 9.2% of patients who
changed distance categories during follow-up, 53.0 and
92.6% remained within 10 and 25 miles of the closest
hemodialysis center, respectively. Of the 714 remote-dwelling
patients, the state of residence was known for all but one
patient (0.14%). The highest proportion (84.0%) lived
in the West (46.5% lived in California and 13.2% resided
in Nevada). Of the remaining remote dwellers, 6.7% lived
in the South (Texas and Oklahoma) and 7.6% in the
Midwest (Kansas, Minnesota, and North Dakota). Remote
dwellers in the Northeastern region resided in Massachusetts
(1.5%).
Likelihood of mortality by distance category
During the median follow-up period of 2.7 years, and
368,569 (50.7%) patients died. Table 2 shows the adjusted
time to death by distance from the closest hemodialysis
center. In the fully adjusted model, patients living 4100
miles from the closest dialysis center had an increased hazard
of death, 1.21 (1.08, 1.37), compared with the referent group
(0–10 miles). When follow-up was not censored at kidney
transplantation, the increased risk of mortality in the remote-
dwelling group was attenuated, although the test for trend
remained statistically significant (Po0.0001). The risk of
death was 1.00 (0.99–1.01), 0.97 (0.95–0.99), 0.94 (0.90–0.98),
and 1.07 (0.96–1.20) for distances of 11–25 miles, 26–45 miles,
46–100 miles, and 4100 miles, respectively (all compared
with the referent of 0–10 miles).
In an additional analysis, we included with the main
cohort the 401,184 dialysis patients who were over 70 years
of age and initiated dialysis during the study period. All
compared with the referent group of 0–10 miles; the risk of
death for 18- to 470-year-olds was 0.99 (0.97–1.00), 0.98
(0.96–0.99), 0.96 (0.93–0.98), and 1.11 (1.02–1.21) for
distances of 11–25 miles, 26–45 miles, 46–100 miles, and
4100 miles, respectively (P for trend o0.0001). When
analyzed separately, patients aged470 years and living more
than 100 miles from the closest hemodialysis center had a
hazard ratio for the risk of death of 1.01 (0.89, 1.14)
compared with those living within 10 miles.
Tests for interaction demonstrated that age (Po0.0001),
race (Po0.0001), diabetes (P¼ 0.0149), cause of ESRD
(Po0.0001), median income (Po0.0001), and insurance
status (Po0.0001), but not sex (P¼ 0.057), all significantly
modified the relationship between distance from the
hemodialysis center and the likelihood of death. Therefore,
we performed analyses that examined the association
between time to death and distance from the closest hemo-
dialysis center, and stratified on these potential confounders
(Figure 1). The point estimate for mortality in the patients
living furthest from the hemodialysis center (4100 miles; as
compared with those living o10 miles) was only significant
in the 18- to 39- and 60- to 70-year-old age categories: 1.57
(95% confidence interval 1.04–2.37) and 1.36 (1.16–1.60),
respectively. Despite the positive test for interaction, the
hazard ratio for mortality for those living furthest away was
similar among those with (1.23 (1.06–1.44)) and without
(1.24 (1.10–1.40)) diabetes as the cause of ESRD. For those
with private insurance, the hazard ratio for higher mortality
was 1.28 (1.01–1.63) and 1.30 (1.10–1.52) for those insured
solely by Medicare.
Likelihood of mortality by rural vs. urban location of
residence
After adjustment for distance from the closest hemodialysis
center, there was no association between rural residence
location and the risk of death (Table 3). A borderline
interaction between rural location of residence and the
distance from the closest hemodialysis center was noted
(P¼ 0.052). However, the risk of death was not appreciably
increased among rural dwellers than among those living in
metropolitan areas within any of the distance categories
(Table 4). The analysis including the patients 470 years old
showed no association between rural residence location and
the risk of death—1.02 (1.02, 1.03) and 1.01 (1.00, 1.02) for
patients residing in micropolitan and rural communities,
respectively, compared with patients residing in metropolitan
areas (data not shown).
DISCUSSION
To our knowledge, this is the first study to evaluate survival for
a large population of hemodialysis patients in the United States
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as a function of distance to the nearest hemodialysis center
while also accounting for urban–rural status. Evaluation of
both of these factors is potentially significant given the
decentralization of dialysis services in the United States; rural
status alone may not adequately measure access to care.
Patients who lived the furthest from the closest hemodial-
ysis center (4100 miles) had a 21% increased risk of death
compared with those living within 10 miles of the closest
center. Although patients living further away from the closest
dialysis center were more likely to live in a rural area than
those living closer, 53.5% of patients living more than 100
miles from the closest dialysis unit lived in either a
metropolitan (population 450,000) or a micropolitan
(population 10,000–50,000) area. Furthermore, when adjusted
Table 1 | Demographics and clinical characteristics among patients initiating chronic hemodialysis, by distance to the closest
hemodialysis center
0–10 Miles, 11–25 Miles, 26–45 Miles, 46–100 Miles, 4100 Miles, P-value
N=558,127 N=135,889 N=26,171 N=5446 N=714
Age*
Mean (s.d.) 53.44 (12.05) 54.27 (11.84) 54.93 (11.60) 55.42 (11.48) 53.32 (12.17) o0.0001
18–39 N (%) 85,740 (15.4) 18,508 (13.6) 3237 (12.4) 611 (11.2) 111 (15.6) o0.0001
40–59 269,160 (48.2) 64,002 (47.1) 12,080 (46.2) 2479 (45.5) 344 (48.2) o0.0001
60–70 203,227 (36.4) 53,379 (39.3) 10,854 (41.5) 2356 (43.3) 259 (36.3) o0.0001
Female 250,663 (44.9) 60,006 (44.2) 11,721 (44.8) 2452 (45.0) 268 (37.5) o0.0001
Race
White 306,978 (55.0) 96,068 (70.7) 20,702 (79.1) 4659 (85.6) 604 (84.6) o0.0001
Black 216,915 (38.9) 33,558 (24.7) 3582 (13.7) 142 (2.6) 38 (5.3) o0.0001
American Indian 5532 (0.99) 3329 (2.4) 1588 (6.1) 591 (10.9) 54 (7.6) o0.0001
Other 28,702 (5.1) 3024 (2.2) 299 (1.1) 54 (1.0) 18 (2.5) o0.0001
Cause of ESRD
Diabetes 264,296 (47.4) 66,818 (49.2) 13,651 (52.2) 3053 (56.1) 362 (50.7) o0.0001
Glomerulonephritis 57,916 (10.4) 14,624 (10.8) 2705 (10.3) 600 (11.0) 87 (12.2) 0.0002
Hypertension 122,685 (22.0) 25,835 (19.0) 4319 (16.5) 670 (12.3) 99 (13.9) o0.0001
Other 113,230 (20.3) 28,612 (21.1) 5496 (21.0) 1123 (20.6) 166 (23.3) o0.0001
BMI430 kg/m2 165,379 (29.6) 43,370 (31.9) 8476 (32.4) 1563 (28.7) 193 (27.0) o0.0001
Comorbidities
CAD 101,044 (18.1) 29,423 (21.7) 6185 (23.6) 1200 (22.0) 115 (16.1) o0.0001
PVD 60,668 (10.9) 17,773 (13.1) 3793 (14.5) 736 (13.5) 74 (10.4) o0.0001
CVD 39,741 (7.1) 10,709 (7.9) 2190 (8.4) 380 (7.0) 54 (7.6) o0.0001
CHF 140,188 (25.1) 36,504 (26.9) 7241 (27.7) 1366 (25.1) 140 (19.6) o0.0001
Cancer 21,322 (3.8) 6196 (4.6) 1240 (4.7) 229 (4.2) 33 (4.6) o0.0001
COPD 28,780 (5.2) 9683 (7.1) 2128 (8.1) 347 (6.4) 33 (4.6) o0.0001
History of drug or alcohol abuse 19,324 (3.5) 3462 (2.6) 594 (2.3) 133 (2.4) 25 (3.5) o0.0001
Smoker 36,476 (6.5) 10,582 (7.8) 2341 (9.0) 429 (7.9) 60 (8.4) o0.0001
Nonambulatory 20,520 (3.7) 5165 (3.8) 1111 (4.3) 147 (2.7) 23 (3.2) o0.0001
eGFR* at the time of dialysis initiation
(s.d.)
8.84 (4.36) 9.09 (4.39) 9.14 (4.43) 8.85 (4.35) 8.68 (4.46) o0.0001
Insurer
Medicare 248,170 (46.1) 60,801 (46.2) 13,321 (52.5) 2686 (51.4) 299 (43.3) o0.0001
Private 162,197 (30.1) 42,344 (32.2) 6421 (25.3) 1235 (23.6) 215 (31.1) o0.0001
Veterans’ 7926 (1.5) 2037 (1.6) 494 (2.0) 109 (2.1) 23 (3.3) o0.0001
Other/none 120,567 (22.4) 26,518 (20.1) 5156 (20.3) 1201 (23.0) 154 (22.3) o0.0001
RUCA score
1.0–3.9 109,355 (20.1) 6199 (4.7) 306 (1.2) 0 (0.00) 125 (19.3) o0.0001
4.0–6.0 397,192 (73.1) 67,260 (51.3) 5519 (22.2) 1161 (22.6) 222 (34.2) o0.0001
46.0 36,901 (6.8) 57,688 (44.0) 19,063 (76.6) 3972 (77.4) 302 (46.5) o0.0001
Median annual income
$0–28,999 134,392 (24.2) 24,593 (18.3) 9559 (37.2) 2279 (42.3) 107 (15.1) o0.0001
$29,000–35,999 127,817 (23.1) 35,401 (26.3) 10,068 (39.1) 2327 (43.2) 141 (19.8) o0.0001
$36,000–45,999 143,388 (25.9) 38,570 (28.7) 5037 (19.6) 584 (10.8) 339 (47.7) o0.0001
$46,000+ 148,778 (26.8) 35,880 (26.7) 1063 (4.1) 200 (3.7) 124 (17.4) o0.0001
Abbreviations: BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease;
eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; PVD, peripheral vascular disease; RUCA, rural–urban commuting area.
Data expressed as N (%), except * mean (standard deviation). Totals do not always add to 100% because of rounding.
Communities were classified as: metropolitan (RUCA 1.0–3.9; cities with population of 450,000 and their associated suburban areas); micropolitan (RUCA 4.0–6.0; towns or
cities with population of 10,000 to 50,000); or rural (RUCA 46.0; towns with population of o10,000).
Data on eGFR, RUCA score, insurer, and median annual income were available for n=667,330, n=726,347, n=692,779, n=705,265, and n=720,647 of the study population,
respectively.
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for distance, rural–urban status was not significantly asso-
ciated with survival. These findings suggest that remote
distance (4100 miles) from the closest dialysis unit, rather
than rural–urban status, better reflects the increased risk of
mortality associated with residence location in US hemodia-
lysis patients. The magnitude of the increased risk among
remote dwellers was relatively small, and was attenuated when
follow-up time after kidney transplantation was included.
This attenuated association was anticipated given the previous
information that remote dwellers (albeit evaluated as distance
from a transplant center) have a higher likelihood of
transplantation than those living closer, and outcomes are
better following transplantation as compared with dialysis.8
We attempted to identify factors that influenced the
association between remote residence location and the risk
of mortality. Despite positive tests for interaction, visual
inspection of the hazards by distance category suggests that
the relationship was similar in groups defined by such factors.
Although we did not find an increased risk of death among
remote dwellers with certain characteristics (such as diabetes;
age 40–59 years; or with hypertension as the underlying cause
of ESRD), it is unclear whether this represents a true
difference or is due to residual confounding by unmeasured
characteristics such as patient or physician preferences. The
risk of death by distance from the closest dialysis center was
not consistently related to age. Furthermore, we did not find
that inclusion of elderly dialysis patients in the study
population (age more than 70 years old) influenced the
relationship between remote residence location and the risk
of mortality. The inclusion of this elderly group of dialysis
patients also did not increase mortality in the rural-dwelling
group. It is possible that, irrespective of location, patients
over the age of 70 years who initiate dialysis are a highly
selected group with a lower comorbid disease burden that is
unaccounted for in our analysis despite adjustment for
comorbid conditions in multivariate models. In a smaller
study from England, the risk of mortality was higher for
incident dialysis patients over 80 years of age; however,
comorbidity was a more significant predictor of outcome
than age.9 Future studies should collect detailed information
on clinical characteristics such as the severity of comorbid
conditions and markers of quality of care for hemodialysis
patients by residence location.
Our results are in keeping with a previously published
study evaluating the association between remote dwelling and
survival in Canadian hemodialysis patients,2 which found a
marked increase in the risk of death from infectious causes
for patients living more than 300 km away. It is possible that
remote-dwelling patients in that study had higher rates of
catheter use and catheter complications, which might have
increased mortality; however, data regarding vascular access
type were not available. Our results regarding remote-
dwelling status and the likelihood of kidney transplantation
are consistent with another large study based on United
States Renal Data System (USRDS) data showing that remote
dwellers (remote from a transplant center) had a similar or
higher likelihood of transplantation compared with patients
living within 15 miles of the kidney transplant center.8 We
speculate that the higher likelihood of transplantation among
remote dwellers from a dialysis center in the current study
may be related to lower comorbid disease burden in this
group, which was not accounted for in our multivariate
analysis, or a higher motivation to pursue transplantation
among remote dwellers because of the travel burden of
dialysis.
Studies based on rural vs. urban residence have reported
equivocal,7 superior,10 or inferior3,6 outcomes for rural
dwellers with chronic kidney disease, compared with
otherwise similar urban dwellers. A British study of 2548
dialysis patients analyzed by health authority reported the
lowest mortality for rural and urban residence and highest
mortality in industrial or mining health authorities.5 The
disparity in survival was not explained by other factors,
including distance to dialysis center. However, this study did
not censor at transplantation, and the majority of patients
were treated with peritoneal dialysis rather than in-center
hemodialysis. Our study included all adult patients starting
hemodialysis over a 12-year period in the United States. We
adjusted for a number of patient and socioeconomic factors
and RUCA score, and also accounted for any potential
disparities in access to transplant by censoring at transplanta-
tion.
It is possible that hemodialysis patients living far from
their dialysis unit have a higher burden of comorbid
conditions than those living closer. However, in our study,
patients living the furthest away had the lowest rates of
Table 2 | Relation between distance to the closest hemodialysis center and time to mortality
Proportion who
died
Model 1:
adjusted for age,
sex, race
Model 2: Model 1
with adjustment
for clinical
characteristicsa
Model 3: Model 2 with
adjustment for
socioeconomic
characteristicsb
0–10 Miles 281,655/558,127 (50.5%) 1.00 1.00 1.00
11–25 miles 69,929/135,889 (51.5%) 1.04 (1.03, 1.05) 1.03 (1.02, 1.04) 1.01 (1.00, 1.02)
26–45 Miles 13,841/26,171 (52.9%) 1.04 (1.02, 1.06) 1.01 (1.00, 1.03) 0.99 (0.97, 1.01)
46–100 Miles 2790/5446 (51.2%) 0.94 (0.90, 0.98) 0.95 (0.92, 0.99) 0.96 (0.92, 1.00)
4100 Miles 354/714 (49.6%) 1.10 (0.99, 1.23) 1.13 (1.01, 1.26) 1.21 (1.08, 1.37)
Results are expressed as hazard ratios with 95% confidence intervals. Models are censored at the time of kidney transplantation.
aCause of end-stage renal disease, body mass index, comorbidities, smoking, drug/alcohol use, nonambulatory status, diabetes, estimated glomerular filtration rate.
bInsurance status, median neighborhood household income, rural–urban commuting area.
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Significant interaction
Diabetes
Yes
No
Insurance
Veterans
Private
Medicare
Other/none
0–10 Miles 1.00
1.00
1.00
1.00
1.00
1.00
1.03 (0.99, 1.08)
0.95 (0.87, 1.04)
0.85 (0.69, 1.04)
0.78 (0.39, 1.56)
0.96 (0.92, 1.01)
1.24 (1.10, 1.40)
0.99 (0.97, 1.01)
1.01 (1.00, 1.02)
1.01 (0.93, 1.09)
1.01 (0.99, 1.03)
1.00 (0.99, 1.02)
1.01 (0.99, 1.03)
1.01 (0.96, 1.06)
0.95 (0.87, 1.05)
0.92 (0.68, 1.24)
0.99 (0.96, 1.01)
0.97 (0.92, 1.02)
1.30 (1.10, 1.52)
1.01 (0.97, 1.06)
0.96 (0.87, 1.07)
1.28 (1.01, 1.63)
0.95 (0.82, 1.10)
0.80 (0.60, 1.09)
1.29 (0.73, 1.29)
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
Adjusted HR (95% CI) P-value
0.0149
<0.0001
0.5 0.7 1.0 1.5 2.0
Significant interaction
Age
18–39 Years
40–59 Years
60–70 Years
0–10 Miles 1.00
1.00
1.00
1.00
1.00
1.00
1.00
0.95 (0.91, 0.99)
0.92 (0.84, 0.99)
0.87 (0.72, 1.05)
1.57 (1.04, 2.37)
1.01 (0.99, 1.02)
1.02 (1.00, 1.03)
1.02 (1.00, 1.03)
1.02 (1.00, 1.04)
1.00 (0.97, 1.03)
0.98 (0.92, 1.04)
0.99 (0.94, 1.03)
0.98 (0.96, 1.00)
0.94 (0.89, 0.99)
0.96 (0.74, 1.26)
1.52 (0.91, 2.52)
1.06 (0.98, 1.14)
1.00 (0.93, 1.08)
0.97 (0.78, 1.20)
0.86 (0.53, 1.39)
0.86 (0.38, 1.91)
0.98 (0.89, 1.09)
1.12 (0.97, 1.30)
1.28 (0.80, 2.05)
1.22 (1.07, 1.39)
1.36 (1.16, 1.60)
1.00 (0.97, 1.03)
0.95 (0.89, 1.02)
1.01 (0.83, 1.22)
0–10 Miles
11–25 Miles
11–25 Miles
25–45 Miles
25–45 Miles
45–100 Miles
45–100 Miles
>100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
Race
White
Black
Native
Other
Adjusted HR (95% CI) P-value
<0.0001
<0.0001
0.70.5 1.0 1.5 2.0
Significant interaction
Median annual income
Low
Median
High
Rich
Cause of ESRD
Diabetes
Hypertension
Glomerulonephritis
Other
0–10 Miles 1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
0.99 (0.97, 1.01)
0.96 (0.93, 1.00)
0.99 (0.93, 1.05)
1.23 (0.90, 1.68)
1.01 (0.99, 1.03)
1.02 (0.99, 1.05)
0.97 (0.91, 1.04)
1.27 (0.99, 1.62)
1.00 (0.99, 1.02)
1.04 (0.99, 1.08)
0.96 (0.84, 1.09)
1.16 (0.98, 1.39)
1.02 (1.00, 1.04)
1.11 (1.00, 1.22)
1.19 (0.92, 1.52)
1.29 (0.95, 1.74)
1.02 (1.01, 1.03)
1.03 (0.97, 1.08)
1.23 (1.06, 1.44)
1.00 (0.98, 1.03)
0.96 (0.92, 1.01)
0.88 (0.79, 0.99)
1.02 (0.75, 1.38)
0.99 (0.95, 1.03)
1.00 (0.92, 1.09)
0.94 (0.80, 1.11)
1.30 (0.80, 2.14)
0.99 (0.96, 1.01)
0.96 (0.91, 1.00)
0.84 (0.75, 0.93)
1.30 (0.99, 1.70)
1.02 (0.99, 1.04)
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
45–100 Miles
>100 Miles
0–10 Miles
11–25 Miles
25–45 Miles
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Figure 1 |The figure shows the adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) associated with the likelihood of
mortality by distance to the closest hemodialysis center (all compared with the referent group of those living within 10 miles).
Models are censored at the time of kidney transplantation and adjusted for patient age, gender, race, cause of end-stage renal disease
(ESRD), diabetic status, median within-neighborhood household income, insurance status, current smoking status, ambulatory status,
comorbid conditions (coronary artery disease, peripheral vascular disease, cerebrovascular disease, congestive heart failure, malignancy,
chronic obstructive pulmonary disease, alcohol or drug dependence), body mass index, and estimated glomerular filtration rate at dialysis
initiation. Tests for interaction were significant at Po0.0001 for age, race, insurance status, median annual income, cause of ESRD, and at
P¼ 0.0149 for diabetic status.
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measured comorbid conditions. There was a modest increase
in the risk of mortality for remote-dwelling patients with
ESRD secondary to diabetes compared with those patients
living closest to their dialysis center, suggesting that the
higher mortality could be related to decreased physician or
health-service access. Yet, just over half of the patients in this
category lived in either a micropolitan or metropolitan area
where better access to physicians and health services would
be expected, as compared with rural areas. A potential
explanation for our results is that the longer distance to travel
to a dialysis center may cause patients to miss or shorten a
dialysis session. Moist et al.4 reported a 20% greater risk of
death for patients with a travel time to dialysis greater than
60 min compared with those patients with a travel time of
15 min or less. Among patients with longer travel times,
transportation issues were identified as a frequent reason to
skip or shorten a dialysis session. Both skipping11 and
shortening12 dialysis sessions have been associated with
increased mortality.
Our study has several limitations. The distance calcula-
tions are based on zip codes and only approximate the true
distance; to minimize bias, we used broad distance categories.
We excluded people without a valid zip code, although this
group accounted for less than 3% of the study population.
We used each patient’s zip code at the time of dialysis
initiation to classify residence location, and this method
could misclassify patients who moved during the study.
However, at follow-up, 90.8% of the patients had remained in
the same distance category. Given that a minority of patients
move further away from specialty care once starting dialysis,2
the true risk of death among remote-dwelling patients would
therefore be expected to underestimate mortality in this
group. Remote residence location has been associated with a
lower risk of initiating dialysis, although we would that
expect this effect would also bias the results toward the null—
with only healthier remote-dwelling patients initiating
dialysis.3 We were unable to reliably identify patients’
performing their own dialysis at home, and such patients
were therefore included in the analysis. However, as the
number of such patients in the United States is low (1756 at
the approximate middle point of our study period), this is
unlikely to have affected our conclusions.13 Our analysis did
not account for changes in dialysis modality that may have
occurred after the initiation of hemodialysis. However, on the
basis USRDS data, the probability of a change in modality
does not differ significantly by rural–urban location.14 We did
not have individual-level data on socioeconomic status, and
because our primary geolocalizing variable was based on zip
code we could not use more precise methods such as block
area addresses to categorize participants with respect to
socioeconomic status. However, results were similar when an
alternative method of adjusting for income (based on zip
code tabulation areas) was used instead (data not shown). We
did not evaluate travel time as a geographical barrier to
access, and it is possible that patients using public
transportation to travel to a dialysis unit would require a
Table 3 | Likelihood of mortality, by rurality of residence location
Proportion who
received a kidney
transplant
Time to death, with censoring
at the time of kidney
transplantation
Proportion who
died
Time to death,
uncensored
Metropolitan
(RUCA 1.0–3.9)
18,493/115,985 (15.9%) 1.00 55,940/115,985 (48.2%) 1.00
Micropolitan
(RUCA 4.0–6.0)
84,874/471,354 (18.0%) 1.02 (1.01, 1.03) 238,317/471,354 (50.6%) 1.01 (1.00, 1.02)
Rural (RUCA
46.0)
21,316/117,926 (18.1%) 1.00 (0.99, 1.02) 62,655/117,926 (53.1%) 0.99 (0.97, 1.00)
Abbreviation: RUCA, rural–urban commuting area.
Results are expressed as hazard ratios with 95% confidence intervals.
Communities were classified as: metropolitan (RUCA 1.0–3.9; cities with population of 450,000 and their associated suburban areas); micropolitan (RUCA 4.0–6.0; towns or
cities with population of 10,000 to 50,000); or rural (RUCA 46.0; towns with population of o10,000).
All analyses were adjusted for age, sex, race, cause of end-stage renal disease, body mass index, comorbidities, smoking, drug/alcohol use, nonambulatory status, median
household income, insurance status, estimated glomerular filtration rate and distance from the closest dialysis center.
Table 4 | Relation between RUCA and time to mortality, in strata defined by distance from the closest hemodialysis center
0–10 Miles 11–25 Miles 26–45 Miles 46–100 Miles 4100 Miles
Metropolitan (RUCA 1.0–3.9) 1 1 1 1 1
Micropolitan (RUCA 4.0–6.0) 1.01 (1.00, 1.02) 1.01 (0.97, 1.05) 0.98 (0.82, 1.17) a 1.21 (0.79, 1.87)
Rural (RUCA 46.0) 0.99 (0.97, 1.01) 0.98 (0.94, 1.02) 0.97 (0.81, 1.15) 1.02 (0.91, 1.14) 0.97 (0.55, 1.72)
Abbreviation: RUCA, rural–urban commuting area.
Results are expressed as hazard ratios with 95% confidence intervals. Data was censored at the time of transplantation.
Communities were classified as: metropolitan (RUCA 1.0–3.9; cities with population of 450,000 and their associated suburban areas); micropolitan (RUCA 4.0–6.0; towns or
cities with population of 10,000 to 50,000); or rural (RUCA 46.0; towns with population of o10,000).
All analyses were adjusted for age, sex, race, cause of end-stage renal disease, body mass index, comorbidities, smoking, drug/alcohol use, nonambulatory status, median
household income, insurance status, estimated glomerular filtration rate and distance from the closest dialysis center.
aInsufficient observations in this cell to compute an estimate.
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similar amount of travel time as remote-dwelling patients
using private transportation. Although the optimal method
of measuring geographical access is unknown, we evaluated
distance by road to the closest dialysis center as it is an
objective determination of geographical access, which is
highly correlated with travel time.15 Finally, we did not have
information on the actual dialysis unit at which patients
received care, and therefore assumed that patients attended
the closest dialysis center.
In conclusion, we found that mortality was higher for
hemodialysis patients living more than 100 miles from the
closest dialysis center compared with those living closer. In
contrast, there was no evidence that the likelihood of death
was higher among rural-dwelling compared with urban-
dwelling patients. Although the number of remote-dwelling
hemodialysis patients in the United States is relatively small,
our results indicate that future studies should evaluate the
specific factors that are related to travel distance, such as cost,
time, and access to transportation—as well as assessing the
quality of care in these patients.
MATERIALS AND METHODS
Study population and data sources
Data from the USRDS were used for this study, which was approved
by the local research ethics review board at the University of Alberta.
We studied incident adult patients, aged 18 to 70 years, who
initiated chronic hemodialysis between 1 January 1995 and 30
September 2007 in the continental United States. The USRDS
provides the zip code for each patient’s residence location at the
time of first renal replacement (dialysis or transplantation), as
well as a listing of centers providing chronic hemodialysis and their
zip codes. The population of each zip code was obtained using data
from the 2000 US census and mapped onto zip-code tabulation
areas.16
Estimation of distance
The geographic coordinates for each five-digit zip code were
determined using the USA 5-digit ZIP Code Database (ZIP Code
Download, Provo, Utah). These coordinates were entered into the
ArcGIS 9.2 software (ESRI Incorporated, Redlands, CA) to
determine the shortest distance by road (in miles) between the
closest hemodialysis center and the residence of each patient at
initiation of hemodialysis.17–19 Distance to the closest hemodialysis
center was categorized corresponding to the 0–75th 475–95th
495–99th 499–99.9th 4 and 499.9th percentiles. To assess the
impact of changes in residence location over time, patients were
categorized into distance categories as above using the zip code
associated with their residence at the time of the last follow-up.
Patient residence data were only available at the zip-code level, and
thus a change in residence location was defined as a move to another
zip code.
Classification of rural status
We used the RUCA code to classify the extent to which the residence
location of each patient was rural or urban.20 RUCA codes are
assigned to each US zip code based on markers of population
density, with values ranging from 1.0 (most urban) to 10.6
(most rural). Information on population density is supplemented
by data on employment commuting to ensure that suburban areas
with low population density in which many residents work in
nearby large urban areas are classified as urban. As in previous
work,20 we classified each patient in the current analysis as
belonging to 1 of 3 mutually exclusive RUCA groups: metropolitan
(RUCA 1.0–3.9; cities with population of 450,000 and their
associated suburban areas); micropolitan (RUCA 4.0–6.0; towns or
cities with population of 10,000 to 50,000; and rural (RUCA 46.0;
towns with population of o10,000).
Statistical analyses
Time to mortality was determined from the date of first
renal replacement using the Kaplan–Meier method, and group
differences were compared with the log-rank test. Patients were
followed up until death or until the end of follow-up (30 September
2007) and censored after time of kidney transplantation. To evaluate
the effect of transplantation on survival according to patient
location, we conducted a sensitivity analysis that did not censor
participants at kidney transplantation. Cox multivariate regression
analysis was performed to determine the likelihood of mortality
among patients in the different distance categories after adjustment
for the following potential confounders: patient age, gender, race (as
submitted to the USRDS on the initial Medical Evidence form:
white, Black, American Indian, other), cause of ESRD (diabetes,
glomerulonephritis, hypertension, other causes), median within-
neighborhood household income (determined by linkage of patient
zip codes to data from the 2000 US census), insurance status
(Medicare only; private insurance only; insured by Department of
Veterans’ Affairs, other or no insurance), current smoking status,
ambulatory status, comorbid conditions (coronary artery disease,
peripheral vascular disease, cerebrovascular disease, congestive heart
failure, malignancy, chronic obstructive pulmonary disease, alcohol
or drug dependence), body mass index, and estimated glomerular
filtration rate at dialysis initiation. In cases in which data were
missing, a category of unknown was created and entered into the
model. To assess the influence of clinically relevant patient
characteristics on the risk of mortality by distance, we repeated
analyses in subgroups defined by combinations of age o50 years,
absence of diabetes, insurance status, and rural–urban residence
location.
Tests for interaction were performed using cross-product terms
in the Cox proportional hazards models. The proportional hazards
assumption was tested using log-negative log plots of the within-
group survivorship probabilities vs. log-time as well as time-
dependent covariates in the Cox model. Statistical significance was
set at Po0.05, and all statistical tests were two sided. Analyses were
performed with SAS version 9.1 (SAS Institute, Cary, NC) and
S-PLUS version 7.0 (TIBCO Software, Palo Alto, CA).
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